Newsroom | 90390 results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrela...

MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, will present significant additions to its comprehensive portfolio of Radiation Therapy Quality Management solutions at the 2025 American Association of Physicists in Medicine (AAPM) Annual Meeting, taking place July 27-29, in Washington, D.C. Attendees are invited to explore new software and hardware innovations designed to help elevate treatment quality, streamline workflows, and support safer care. Premiering at AAPM 202...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that four abstracts highlighting clinical progress across its botensilimab and balstilimab immunotherapy programs have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place in Berlin, Germany from October 17-21. The highlight is an oral presentation that will feature emerging survival plateaus from a study of botensilimab plus balst...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Provides Regulatory Update on Elinzanetant for the Treatment of Moderate to Severe Hot Flashes Due to Menopause...

DUBLIN--(BUSINESS WIRE)--The "Pertussis Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global pertussis market includes various vaccine formulations such as whole-cell vaccines and acellular vaccines, which are used in pediatric and adult immunization schedules. These vaccines are being continually improved for safety, efficacy, and patient acceptance. Acellular v...

DUBLIN--(BUSINESS WIRE)--The "Tumor Ablation Market (By Technology, Treatment Mode, Application, End-User, Regional Analysis), Company Profiles, Product Portfolio, Recent Developments, Key Trends and Market Dynamics - Global Forecast (2025 - 2032)" report has been added to ResearchAndMarkets.com's offering. The global tumor ablation market is expected to reach US$ 4.15 billion by 2032, from US$ 1.67 billion in 2024. Technological advancements to enhance accuracy, portability, and cost-effective...

NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain--(BUSINESS WIRE)--Prilenia Therapeutics B.V. and Ferrer today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the refusal of the marketing authorization for pridopidine’s marketing authorization application for Huntington’s disease (HD). We are disappointed, but undeterred in our commitment to bring what we believe is an effective therapy to patients and will explo...

DUBLIN--(BUSINESS WIRE)--The "The Global Market for Synthetic Biology 2026-2036" report has been added to ResearchAndMarkets.com's offering. The synthetic biology market is experiencing robust growth at a compound annual growth rate (CAGR) of 20.6-28.63%, fueled by several converging factors. The Global Synthetic Biology (Synbio) Market 2026-2036 represents the most comprehensive analysis of one of biotechnology's fastest-growing sectors, providing essential intelligence for investors, industry...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, acknowledges that the Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the conditional marketing authorization (CMA) for ELEVIDYS (delandistrogene moxeparvovec) in ambulatory individuals ages three to seven years for the treatment of Duchenne muscular dystrophy (DMD). “While we are disappointed by the CHMP’s negative opinion,...

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) will report its second quarter 2025 financial results on Wednesday, August 6, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which...